Analysts Anticipate Zoetis Inc. (NYSE:ZTS) Will Announce Earnings of $1.22 Per Share

Wall Street brokerages expect that Zoetis Inc. (NYSE:ZTSGet Rating) will post $1.22 earnings per share for the current fiscal quarter, according to Zacks Investment Research. Six analysts have issued estimates for Zoetis’ earnings, with the lowest EPS estimate coming in at $1.16 and the highest estimate coming in at $1.27. Zoetis posted earnings of $1.19 per share in the same quarter last year, which would suggest a positive year over year growth rate of 2.5%. The business is scheduled to issue its next quarterly earnings report on Monday, January 1st.

According to Zacks, analysts expect that Zoetis will report full year earnings of $5.07 per share for the current fiscal year, with EPS estimates ranging from $4.99 to $5.15. For the next financial year, analysts forecast that the business will report earnings of $5.79 per share, with EPS estimates ranging from $5.57 to $5.91. Zacks’ earnings per share averages are an average based on a survey of research analysts that cover Zoetis.

Zoetis (NYSE:ZTSGet Rating) last released its quarterly earnings results on Thursday, May 5th. The company reported $1.32 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.23 by $0.09. The business had revenue of $2 billion during the quarter, compared to the consensus estimate of $1.98 billion. Zoetis had a return on equity of 49.62% and a net margin of 26.27%. The company’s quarterly revenue was up 6.9% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.26 EPS.

ZTS has been the topic of a number of research analyst reports. StockNews.com downgraded Zoetis from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, April 26th. Citigroup cut their target price on Zoetis from $232.00 to $208.00 and set a “neutral” rating on the stock in a research note on Wednesday, March 9th. Finally, The Goldman Sachs Group cut their target price on Zoetis from $237.00 to $208.00 and set a “buy” rating on the stock in a research note on Thursday. Three research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat.com, Zoetis has an average rating of “Buy” and an average target price of $231.88.

Shares of NYSE ZTS opened at $162.56 on Monday. Zoetis has a twelve month low of $156.67 and a twelve month high of $249.27. The stock’s 50 day moving average price is $182.03 and its 200-day moving average price is $201.59. The company has a market capitalization of $76.51 billion, a PE ratio of 37.28, a PEG ratio of 2.66 and a beta of 0.77. The company has a quick ratio of 1.58, a current ratio of 2.25 and a debt-to-equity ratio of 1.12.

The firm also recently announced a quarterly dividend, which will be paid on Thursday, September 1st. Shareholders of record on Thursday, July 21st will be issued a dividend of $0.325 per share. The ex-dividend date of this dividend is Wednesday, July 20th. This represents a $1.30 dividend on an annualized basis and a yield of 0.80%. Zoetis’s payout ratio is 29.82%.

In other Zoetis news, EVP Roman Trawicki sold 6,000 shares of the firm’s stock in a transaction dated Wednesday, March 16th. The stock was sold at an average price of $188.15, for a total value of $1,128,900.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, EVP Roxanne Lagano sold 2,167 shares of the firm’s stock in a transaction dated Tuesday, April 26th. The shares were sold at an average price of $178.96, for a total value of $387,806.32. Following the transaction, the executive vice president now directly owns 23,687 shares in the company, valued at $4,239,025.52. The disclosure for this sale can be found here. In the last ninety days, insiders sold 50,557 shares of company stock worth $9,589,496. Insiders own 0.12% of the company’s stock.

Several hedge funds and other institutional investors have recently made changes to their positions in ZTS. Morgan Stanley raised its holdings in shares of Zoetis by 4.6% during the 2nd quarter. Morgan Stanley now owns 7,561,487 shares of the company’s stock valued at $1,409,158,000 after buying an additional 333,952 shares in the last quarter. New World Advisors LLC purchased a new position in shares of Zoetis during the 3rd quarter valued at about $341,000. B. Riley Wealth Management Inc. raised its holdings in shares of Zoetis by 49.7% during the 3rd quarter. B. Riley Wealth Management Inc. now owns 2,351 shares of the company’s stock valued at $456,000 after buying an additional 781 shares in the last quarter. NorthRock Partners LLC raised its holdings in shares of Zoetis by 40.0% during the 3rd quarter. NorthRock Partners LLC now owns 1,628 shares of the company’s stock valued at $316,000 after buying an additional 465 shares in the last quarter. Finally, BerganKDV Wealth Management LLC raised its holdings in shares of Zoetis by 29.5% during the 3rd quarter. BerganKDV Wealth Management LLC now owns 781 shares of the company’s stock valued at $152,000 after buying an additional 178 shares in the last quarter. 90.73% of the stock is currently owned by institutional investors.

Zoetis Company Profile (Get Rating)

Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.

Featured Stories

Get a free copy of the Zacks research report on Zoetis (ZTS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.